The impact of COVID-19 on Clinical Trials has been enormous. With so much information available, CT:IQ has gathered all the COVID-19 relevant resources and guidance, locally and internationally, for our sector and will continue to keep this up to date to keep you informed.

Clinical trial conduct during the COVID-19 pandemic

Beyond COVID-19: A solution-focussed forum

ACTA, PRAXIS Australia, ARCS Australia and CT:IQ have come together to create Beyond COVID-19: a solution-focussed forum after identifying a need for the clinical trial sector to collaborate and share information.

Clinical trialists can instantly share their knowledge, assist with responses and point each other to useful resources or contacts; from ethics to telehealth, pharmaceutical supply to remote monitoring to guide.  Solving problems is at the heart of clinical trials, and the COVID-19 pandemic has seen the sector becoming more agile; adapting existing trials, finding new ways to commence planned trials, or moving quickly to help test treatments and solve the riddles of coronavirus.

The pathway out of the pandemic will also see some twists and turns, more problem-solving for the sector and an important discussion around which of the adaptations and innovations we should sustain – where Beyond COVID-19: a solution-focussed forum will continue to be a sharing space.

It is open for anyone to read, and registration to participate is simple.

COVID-19: Guidance

COVID-19: Resources

COVID-19: International Guidance

COVID-19: Clinical Trials Registries

COVID-19: Developing Medicines for Treatment or Prevention - Guidance

CT:IQ 2018 launch materials – learn from Emeritus Professor Ian Chubb just how clinical trials made a difference to his life.